2017
DOI: 10.1002/cbic.201700402
|View full text |Cite
|
Sign up to set email alerts
|

Phage Display on the Anti‐infective Target 1‐Deoxy‐d‐xylulose‐5‐phosphate Synthase Leads to an Acceptor–Substrate Competitive Peptidic Inhibitor

Abstract: Enzymes of the 2‐C‐methyl‐d‐erythritol‐4‐phosphate pathway for the biosynthesis of isoprenoid precursors are validated drug targets. By performing phage display on 1‐deoxy‐d‐xylulose‐5‐phosphate synthase (DXS), which catalyzes the first step of this pathway, we discovered several peptide hits and recognized false‐positive hits. The enriched peptide binder P12 emerged as a substrate (d‐glyceraldehyde‐3‐phosphate)‐competitive inhibitor of Deinococcus radiodurans DXS. The results indicate possible overlap of the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
9
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 7 publications
(9 citation statements)
references
References 48 publications
(91 reference statements)
0
9
0
Order By: Relevance
“…However, off-target activity in bacteria is likely due to the reactive catechol functionality. Using phage display, the Hirsch lab has discovered the first peptide-based d -GAP competitive inhibitor ( 11 ), 40 albeit with weak enzyme inhibitory activity ( K i = 113 μM).…”
Section: Selective Inhibition Of Dxp Synthasementioning
confidence: 99%
“…However, off-target activity in bacteria is likely due to the reactive catechol functionality. Using phage display, the Hirsch lab has discovered the first peptide-based d -GAP competitive inhibitor ( 11 ), 40 albeit with weak enzyme inhibitory activity ( K i = 113 μM).…”
Section: Selective Inhibition Of Dxp Synthasementioning
confidence: 99%
“…The rational development of D-GAP competitive inhibitors has been more challenging with both known D-GAP competitive inhibitors emerging from screening approaches. 20,21…”
Section: Introductionmentioning
confidence: 99%
“…Inhibitors of DXP synthase resembling the substrate or cofactor have been pursued. Among these are the alkylacetylphosphonates (alkylAPs), which are known to inhibit ThDP-dependent pyruvate decarboxylase enzymes. , The acetylphosphonate moiety mimics the natural ketoacid substrate, pyruvate, to form a reversible covalent phosphonolactyl ThDP intermediate [PLThDP (Figure )]. ,, While methylacetylphosphonate (MAP) and its structural analogue, acetylphosphinate (AcPhi), have been useful mechanistic probes in ThDP enzymology, a lack of potency and poor selectivity have limited their usefulness as antimicrobial agents. The rational development of d -GAP competitive inhibitors has been more challenging with both known d -GAP competitive inhibitors emerging from screening approaches. , …”
mentioning
confidence: 99%
See 1 more Smart Citation
“…Moreover, they have been explored as therapeutic agents, such as vaccines, [20] immunotherapy agents, [21] and inhibitors of a target protein. [22][23][24][25] For example, the world's best-selling drug, HUMIRA, was discovered using the phage display technology. We recently developed a novel biopanning strategy to discover small peptides that can specifically bind to programmed death-ligand 1 (PD-L1) and block its interaction with the programmed cell death 1 (PD-1).…”
Section: Introductionmentioning
confidence: 99%